Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1689 • 2016 ACR/ARHP Annual Meeting
Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, M. Elaine Husni², Catherine L. Shuler³, Russel T. Burge³, Chen-Yen Lin³, Chin H. Lee³ and D Gladman⁴, ¹Tufts University School of Medicine, Boston, MA, ²Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: PsA has a negative impact on patients’ quality of life, physical function, and work productivity. Ixekizumab (IXE) is an IgG4 mAb that binds with…
Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Raimon Sanmarti¹, Jose Inciarte-Mundo¹, Paula Estrada², Maria García Manrique³, Javier Narváez⁴, Antonio Gomez-Centeno³, Jesús Rodríguez-Moreno⁴, Mariona Pascal⁵ and Jordi Yagüe⁵, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, ³Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ⁵Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
Abstract Number: 158 • 2016 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound Is a Sensitive Imaging Tool for the Assessment of Dynamic Changes of Bone Erosions in Inflammatory Arthritis: A Comparative Analysis with High-Resolution Peripheral Quantitatve Computed Tomography
Stephanie Finzel^1,2, Marina Backhaus³, Sebastian Kraus⁴, Georg Schett⁵ and Reinhard Voll⁶, ¹Department of Rheumatology and Clinical Immunology, Medical Faculty, University Medical Center, University of Freiburg, Freiburg, Germany, ²Department of Internal Medicine III, Rheumatology and Immunology, University of Erlangen, 91054, Germany, ³Rheumatology, Park-Klinik Weissensee, Berlin, Germany, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Dpt. Rheumatology & Clinical Immunology and Centre for Chronic Immunodeficiency, University Hospital Freiburg, University Medical Center, University of Freiburg, Freiburg, Germany
Background/Purpose: Correct detection of bone erosions is crucial both for diagnosis and for monitoring of treatment response in patients with inflammatory joint diseases. Musculoskeletal ultrasound…
Abstract Number: 1694 • 2016 ACR/ARHP Annual Meeting
Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?
Laura C. Coates^1,2, Elizabeth M.A. Hensor^1,3, Paul Emery⁴, Philip G. Conaghan¹ and Philip S. Helliwell⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Tight Control of PsA (TICOPA) study was the first to address treat to target in PsA using the minimal disease activity (MDA)…
Abstract Number: 2747 • 2016 ACR/ARHP Annual Meeting
Dapsa-28 May be Used Instead of Dapsa-66/68 in Psoriatic Arthritis
Umut Kalyoncu, Ozun Bayndır, Mustafa Ferhat Oksuz, Gezmis Kimyon, Abdulsamet Erden, Sule Yavuz, Gozde Cetin, Orhan Kucuksahin, Levent Kilic, Ahmet Omma, Cem Ozisler, Dilek Solmaz, Ahmet Mesut Onat, Bunyamin Kisacik, Duygu Ersozlu Bakirli, Muhammet Cinar, Abdurrahman Tufan, Fatih Yildiz, Ridvan Mercan, Timucin Kasifoglu, Baris Yilmazer, Sema Yilmaz, Kenan Aksu, Sukran Erten, Mehmet Sayarlioglu, Ediz Dalkilic, Servet Akar, Cengizhan Acikel, Muge Aydin Tufan, Ayse Balkarli, Esen Kasapoglu-Gunal, Soner Senel, Senol Kobak, M Tuncay Duruoz, Atalay Dogru, E.Figen Tarhan, Meryem Can, Lutfi Akyol, Seval Pehlevan, Funda Erbasan, Fatos Arslan, Adem Kucuk, Emel Gonullu, Yasemin Kabasakal, Mehmet Sahin, Nilgun Atakan and Sibel Z. Aydin, PsART study group, Ankara, Turkey
Background/Purpose: Disease Activity index for Psoriatic Arthritis (DAPSA) originally developed from patients with reactive arthritis and validated in psoriatic arthritis (PsA) patients. DAPSA includes…
Abstract Number: 543 • 2016 ACR/ARHP Annual Meeting
Synovial Features of Rheumatoid Arthritis and Psoriatic Arthritis Differ in Patients in Clinical and Ultrasound Remission after Anti-TNF Therapy
Stefano Alivernini¹, Luca Petricca¹, Laura Bui², Barbara Tolusso¹, Gabriele Di Sante¹, Roberta Benvenuto², Anna Laura Fedele¹, Elisa Gremese¹ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Histopathology - Institute of Pathology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Persistent disease remission is the major goal of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) treatment. The combined use of clinical and ultrasound selection…
Abstract Number: 1703 • 2016 ACR/ARHP Annual Meeting
Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial
Peter Nash¹, Kamal Ohson², Jessica Walsh³, Nikolay Delev⁴, Dianne Nguyen⁴, Lichen Teng⁴, Juan J Gomez-Reino⁵ and Jacob A Aelion⁶, ¹University of Queensland, Brisbane, Australia, ²Memorial University of Newfoundland, St. John's, NF, Canada, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴Celgene Corporation, Summit, NJ, ⁵Hospital Clinico Universitario, Santiago, Spain, ⁶West Tennessee Research Institute, Jackson, TN
Background/Purpose: ACTIVE is the first apremilast (APR) trial that evaluated time to onset of efficacy beginning at Wk 2 in psoriatic arthritis (PsA) patients (pts)…
Abstract Number: 2930 • 2016 ACR/ARHP Annual Meeting
Specific Metabolic and Functional Changes in Peripheral CD8+ T Cells Specifically Distinguish RA from PSA and SPA
Rui Carvalho¹, Christine Tucher², Lars Tykocinski², Susanne Neu², Karel Klika³, H.-M. Lorenz² and Margarida Souto-Carneiro², ¹Life Sciences Department, FCTUC, Center for Functional Ecology, University of Coimbra, Coimbra, Portugal, ²Rheumatology, Department of Rheumatology, University of Heidelberg, Heidelberg, Germany, ³German Cancer Research Center, Heidelberg, Germany
Background/Purpose: Studies by our team and others have shown that CD8 T cells (CD8s) in RA have a pro-inflammatory, cytotoxic effector phenotype and may, therefore,…
Abstract Number: 629 • 2016 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany
Klaus Krüger¹, GR Burmester², Siegfried Wassenberg³, Martin Bohl-Buehler⁴ and Matthias H. Thomas⁵, ¹Praxiszentrum St. Bonifatius, München, Germany, ²Charité – University Medicine Berlin, Berlin, Germany, ³Rheumazentrum, Ratingen, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various randomized clinical trials with patients eligible for clinical studies. Data from patient-reported outcomes (PROs)…
Abstract Number: 1711 • 2016 ACR/ARHP Annual Meeting
Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials
Dafna D. Gladman¹, Arthur Kavanaugh², Juan J. Gomez-Reino³, Jürgen Wollenhaupt⁴, Maurizio Cutolo⁵, Georg Schett⁶, Eric Lespessailles⁷, Melissa McIlraith⁸, ChiaChi Hu⁸, Christopher J. Edwards⁹, Charles A. Birbara¹⁰ and Philip J Mease¹¹, ¹Toronto Western Hospital, Toronto, ON, Canada, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³Hospital Clinico Universitario, Santiago, Spain, ⁴Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁵University of Genova, Genova, Italy, ⁶University of Erlangen-Nuremberg, Erlangen, Germany, ⁷University of Orléans, Orléans, France, ⁸Celgene Corporation, Summit, NJ, ⁹University Hospital Southampton, Southampton, United Kingdom, ¹⁰University of Massachusetts Medical School, Worcester, MA, ¹¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Of the multiple manifestations of psoriatic arthritis (PsA), enthesitis and dactylitis are hallmark features that affect many patients (pts), can lead to pain and…
Abstract Number: 2983 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo‑Controlled, Phase 3 Trial
Philip J Mease¹, Stephen Hall², Oliver FitzGerald³, Désirée van der Heijde⁴, Joseph F Merola⁵, Francisco Avila-Zapata⁶, Dorata Cieślak⁷, Daniela Graham⁸, Cunshan Wang⁹, Sujatha Menon⁹, Thijs Hendrikx⁸ and Keith Kanik⁹, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Cabrini Health and Monash University, Melbourne, VIC, Australia, ³Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College, Dublin, Ireland, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan S.C.P., Yucatán, Mexico, ⁷Poznan University, Poznan, Poland, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). This study evaluated tofacitinib efficacy and safety vs placebo…
Abstract Number: 930 • 2016 ACR/ARHP Annual Meeting
How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁶, Glenn Haugeberg⁷ and Anne Grete Semb¹, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Martina Hansens Hospital, Bærum, Norway
Background/Purpose: The EULAR recommendations for cardiovascular disease (CVD) risk management in patients with inflammatory joint diseases (IJD) states that CVD risk assessment should be considered…
Abstract Number: 1713 • 2016 ACR/ARHP Annual Meeting
Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials
Philip J Mease¹, Dafna D Gladman², Juan J Gomez-Reino³, Stephen Hall⁴, Arthur Kavanaugh⁵, Eric Lespessailles⁶, Georg Schett⁷, Kamal Shah⁸, Lichen Teng⁸ and Jürgen Wollenhaupt⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³Hospital Clinico Universitario, Santiago, Spain, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶University of Orléans, Orléans, France, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Summit, NJ, ⁹Schön Klinik Hamburg-Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune activity in psoriatic arthritis (PsA) patients. PALACE 1 (NCT01172938), 2 (NCT01212757), and 3…
Abstract Number: 3085 • 2016 ACR/ARHP Annual Meeting
Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?
Brigitte Michelsen^1,2, Karen M Fagerli¹, Elisabeth Lie¹, Hilde Berner Hammer³, Glenn Haugeberg^4,5, Eirik K Kristianslund¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁵Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Depression and anxiety are reported to predict poorer treatment outcomes in rheumatoid arthritis (RA).1 Whether this can be confirmed in larger, prospective studies as…
Abstract Number: 938 • 2016 ACR/ARHP Annual Meeting
Prevalence of Non-Radiographic Axial Spondyloarthritis in Psoriatic Arthritis – a Single Center Observational Study
Victoria Furer¹, Moshe Stark², Hagit Matz³, David Levartovsky⁴, Jonathan Wallman⁵, Irena Wigler⁶, Hagit Sarvagyl-Maman⁷, Ofir Elalouf⁸, Sara Borok Lev-Ran⁹, Daphna Paran⁶, Gideon Flusser¹⁰, Iddo Drukman¹⁰, Iris Eshed¹¹ and Ori Elkayam¹², ¹Rheumatology, Tel Aviv Sourasky Medical Center, The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Tel Aviv, Israel, ³Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel, ⁴Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁵Rheumatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁷Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ⁸Rheumatology, Tel Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, ⁹Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine,Tel Aviv University, Tel AViv, Israel, ¹⁰Radiology, Tel Aviv Medical Center, Tel Aviv, Israel, ¹¹Department of Radiology, Sheba Medical Center, Israel, Tel Hashomer, Israel, ¹²Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Sacroiliitis, as detected by plain radiographs of the sacroiliac joints (SIJ), has been reported in a third of the psoriatic arthritis (PsA) population. (1)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].